Table 1 Demographic characteristics, clinical features, laboratory findings and clinical outcome of all MIS-C patients

Demographic and clinical characteristics at admission, n (%)

Age in years, median (min.-max.)

7 (5 weeks − 17 years)

Male sex

32 (60.4%)

Comorbidities, n (%)

11 (20.8%)

Fever, days at admission, median

5

Gastrointestinal symptoms

38 (71.7%)

Mucocutaneous symptoms

40 (75.5%)

Cardiovascular symptoms

30 (56.6%)

Respiratory symptoms

19 (35.8%)

Neurological symptoms

5 (9.4%)

Renal symptoms

9 (17%)

SARS-CoV-2 test results, n (%)

Positive RT-PCR

12 (22.6%)

Positive serology

42/51 (82.4%)

Laboratory confirmed SARS-CoV-2 infection

47 (88.7%)

Epidemiological link to confirm SARS-CoV-2 infection

20 (37.7%)

Cardiogical disorders, n (%)

Myocardial dysfunction

17 (32%)

Coronary artery abnormalities

6 (11.3%)

Coronary artery aneurysm

0

Mitral valve regurgitation

14 (26.6%)

Pericardial effusion

9 (17%)

Abnormal ECG

17 (32.1%)

Laboratory test at admission (normal range), median (IQR), % of aberrant values

Platelets (150–400 Giga/L)

248 (140–332)

43.40%

White blood cell count (4.5–11.5 Giga/L)

12 (9.23–17.07)

58.49%

Absolute lymphocyte count (0.9-4 Giga/L)

1.43 (0.95–2.84)

28.30%

C-reactive protein (< 2.2 mg/L)

171.91 (103.16-211.74)

98.11%

PCT (< 0.5 ug/L)

1.83(0.72–3.96)

75.47%

Interleukin-6 (< 7 ng/L)

186.8 (70.57-331.45)

92.45%

Cardiac TnT (< 10 ng/L)

19.83 (4.78–35.64)

67.92%

Pro-BNP (< 191.1 ng/L) < 191,1

2609.83 (935.34-9108.19)

79.25%

Ferritin (13–150 ug/L)

420 (230.5-626.9)

84.91%

INR

1.035 (0.96–1.11)

79.25%

D-dimer (< 0.5 mg FEU/L)

2.42 (1.48–4.25)

N/A

Albumin (35–52 g/L)

34 (30–36)

92.45%

Urea (1.4–6.8 mmol/L)

4.2 (3.6–6.4)

45.28%

Creatinine (26–88 umol/L)

42 (33–55)

20.75%

GPT (< 40 U/L)

20.5 (14-35.25)

7.55%

Bicarbonate (24 mmol/L)

24.8 (22.82–26.32)

18.87%

Clinical outcome, n (%)

Days of pediatric intensive care unit (median)

3

Oxygen therapy

8 (15.1%)

Non-invasive respiratory support

3 (5.7%)

Invasive mechanical ventilation

2 (3.8%)

Vasoactive drugs

18 (34%)

Death

0